Search

Displaying results 1181 - 1190 of 10000 in total
  1. Drug

    Evalstotug

    go.drugbank.com/drugs/DB19410
    Investigational

    Evalstotug is under investigation in clinical trial NCT05271604 (A Phase 2 Open Label Study of BA3021 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck).

    Synonyms: Immunoglobulin G1-kappa, anti-[Homo sapiens CTLA4 (cytotoxic T-lymphocyte associated protein 4, CTLA-4, CD152)], monoclonal antibody, Immunoglobulin G1 [de-448-lysine], anti-(human cytotoxic T-lymphocyte-associated protein 4) (human monoclonal BA3071 γ1-chain), disulfide with human monoclonal BA3071 κ-chain, dimer
  2. Drug

    Orphenadrine

    go.drugbank.com/drugs/DB01173
    ApprovedInvestigational

    A muscarinic antagonist used to treat drug-induced parkinsonism and to relieve pain from muscle spasm.

    Synonyms: N,N-dimethyl-2-[(o-methyl-α-phenylbenzyl)oxy]ethylamine, N,N-Dimethyl-2-(alpha-2-tolylbenzoyloxy)ethylamineMixtures: MERA, MYOGESIC-B
  3. Drug

    OT-730

    go.drugbank.com/drugs/DB16112
    Investigational

    OT-730 is under investigation in clinical trial NCT00753168 (Phase 1-2 Evaluation of OT-730 Eye Drops in Reducing the Intraocular Pressure in Patients With Ocular Hypertension or Open-angle Glaucoma).

  4. Pathway

    Intracellular Signalling Through Adenosine Receptor A2a and Adenosine

    smpdb.ca/view/SMP0000320
    Signaling

    The adenosine receptor A2a activates G(s) proteins which lead to the activation of adenylyl cyclase which produces the secondary messenger cAMP. cAMP activates PKA (protein kinase A) which phosphorylates

    Drugs: ATP · Adenosine · Magnesium cation · Zinc · Cyclic adenosine monophosphate · Pyrophosphoric acid
    Enzymes: Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-12, Guanine nucleotide-binding protein G(s) subunit alpha isoforms short
  5. Drug

    Tocopherol

    go.drugbank.com/drugs/DB11251
    ApprovedInvestigational

    Tocopherol exists in four different forms designated as α, β, δ, and γ. They present strong antioxidant activities, and it is determined as the major form of vitamin E. … Tocopherol, as a group, is composed of soluble phenolic compounds that consist of a chromanol ring and a 16-carbon phytyl chain.

    Mixtures: Anti-Stretch Mark, Udamin SpCategories: Vitamin E, tocopherol (vit E)
  6. Drug

    Nusinersen

    go.drugbank.com/drugs/DB13161
    ApprovedInvestigational

    FDA in December, 2016 as Spinraza for the treatment of children and adults with spinal muscular atrophy (SMA). It is adminstrated as direct intrathecal injection.

    Categories: Survival Motor Neuron-2-directed RNA InteractionProducts: SPİNRAZA 12 MG/5 ML INTRATEKAL ENJEKSİYONLUK ÇÖZELTİ, 1 ADET, SPINRAZA ®12 MG SOLUCION INYECTABLE
  7. Drug

    Voretigene neparvovec

    go.drugbank.com/drugs/DB13932
    ApprovedInvestigational

    It is not pathogenic and it causes a very mild immune response. … Voretigene Neparvovec-rzyl (VN-rzyl) is an adeno-associated virus vector-based gene therapy.[L1094] An adeno-associated virus is a small virus that infects humans and other primates.

  8. Drug

    Odanacatib

    go.drugbank.com/drugs/DB06670
    Investigational

    Odanacatib is an inhibiter of cathepsin K which was originally developed be Merck & Co as a new treatment for osteoporosis [A19388].

    Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates
  9. Drug

    Encorafenib

    go.drugbank.com/drugs/DB11718
    ApprovedInvestigational

    [L12216] This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and secretion. … Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations.

    Categories: P-glycoprotein inhibitors, P-glycoprotein substratesProducts: BRAFTOVI® 75 MG CÁPSULAS
  10. Drug

    Davesomeran

    go.drugbank.com/drugs/DB17091
    ApprovedInvestigational

    [L43882] A phase 2 and 3 open-label study in participants 18 years or older who had previously received a two-dose primary series and one booster dose of Moderna COVID-19 Vaccine demonstrated that the … Similar to the previous Moderna COVID-19 vaccine, Moderna Bivalent vaccine encodes the full-length pre-fusion stabilized spike (S) protein to elicit an immune response.

    Mixtures: Spikevax Bivalent (original / Omicron Ba.4/5)